Certara, Inc.

Certara provides biosimulation software and technology-enabled consulting services to support model-informed drug development. Its primary solutions include mechanistic and empirical biosimulation platforms, scientific informatics, preclinical and clinical data automation tools, and regulatory science software. These offerings help clients design clinical trials, standardize research data, predict drug effects, and streamline regulatory submissions. The company serves biopharmaceutical and biotechnology companies, contract research organizations, academic institutions, and government bodies, alongside customers in animal health, crop science, and medical devices.

The company operates globally, with its software licensed across seventy countries and utilized by twenty global regulatory agencies. As of year-end 2025, it employs over 1,500 professionals across twenty-eight countries, including the United States, Europe, and Asia. The provided text does not identify the location of its corporate headquarters.

Summary of the business section of Certara's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“Table of Contents unavailability of critical data and confidential or proprietary information (our own or that of third parties, including information about our customers and employees) and the disruption of business operations. … In addition, our collection, use, disclosure, protection and other processing of information is subject to related contractual requirements. Compliance with such laws and related contractual requirements may require changes to our information processing practices and m”